SNDX Stock Risk & Deep Value Analysis
Syndax Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SNDX Stock
We analyzed Syndax Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SNDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is SNDX Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Low
What Are the Red Flags for SNDX?
- ⚠
Lower-than-expected revumenib commercial uptake or sales guidance
- ⚠
Emergence of competitive therapies with superior efficacy or safety profiles
- ⚠
Unexpected safety signals for revumenib post-marketing
- ⚠
Adverse clinical trial results for pipeline candidates
Unlock SNDX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Syndax Pharmaceuticals Inc (SNDX) Do?
Market Cap
$1.88B
Sector
Healthcare
Industry
Biotechnology
Employees
270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Visit Syndax Pharmaceuticals Inc WebsiteIs SNDX Stock Undervalued?
Unlock the full AI analysis for SNDX
Get the complete DVR score, risk analysis, and more
Does SNDX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily derived from patent protection and regulatory exclusivity for revumenib, which will likely endure for 10-15 years post-launch. Being first-in-class for a targeted indication establishes an early and strong market position.
Moat Erosion Risks
- •Development of a more effective or safer menin inhibitor by a competitor
- •Introduction of entirely new therapeutic modalities that bypass the menin pathway
- •Patent challenges or unexpected generic entry
SNDX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive SNDX Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Early March 2026)
- •Initial Revumenib Commercial Sales Updates (Q1 2026 results, expected May 2026)
- •Presentation of additional clinical data for revumenib in various settings (e.g., medical conferences)
Medium-Term (6-18 months)
- •Regulatory submission for revumenib in additional indications or geographies
- •Pipeline updates and initiation of new clinical trials for earlier-stage assets
- •Continued growth and milestones from Axatilimab partnership with Incyte
Long-Term (18+ months)
- •Establishment of revumenib as standard of care in KMT2A-rearranged AML/ALL and potential label expansions
- •Successful development and commercialization of next-generation oncology assets
- •Potential acquisition target by a larger pharmaceutical company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SNDX?
- ✓
Acceleration in revumenib sales growth rates and positive commercial guidance
- ✓
Positive clinical trial readouts for revumenib in additional indications or earlier lines of therapy
- ✓
Effective cash management and pipeline progression without significant dilution
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SNDX (Syndax Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
